BioWorld MedTech

Oct. 23, 2014

View Archived Issues

Inside the Beltway:FDA custom device final guidance allows five devices per indication

Beta-O2 treats first patient in Bio-Artificial pancreas trial

Daily M&A: OxySure Systems and Estill to merge, financial details not disclosed

Financings: Nanosphere's 40M share offering could raise more than $21 million

World in Review: Foundation Medicine, WuXi, to offer profiling to biopharma in China

Grants:Antigen Discovery gains SBIR from NIH to develop HIV Microarray chip

Agreeements/contracts

Briefly Noted

Products

MDD's Orthopedics Extra

United European Gastroenterology Meeting: Robotic colonoscopy said to eliminate pain, reduces costs

VIENNA — Discomfort is the leading reason people give for not undergoing a colonoscopy, and the leading cause of non-compliance with this gold standard for colorectal cancer screening. Read More

Reimbursement Review:Rising middle class offset by price pressure in India med-tech market

Today's news in brief

BioWorld

BioWorld briefs for May 2, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 2, 2025.

CMS vows to put more emphasis on MA plans’ prior authorization

BioWorld MedTech

Physicians aren’t the only ones who see prior authorization (PA) practices as a significant problem, but John Brooks, deputy administrator at CMS, told a med tech...

Filling the NIH funding gap to protect biopharma research

BioWorld

The Trump administration’s broad slash to university research budgets raises pertinent questions over impacts to the biopharma ecosystem, specifically how a...

US flag, stock market chart, White House

100 days of uncertainty

BioWorld

The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...